PerkinElmer Acquires Spectral Genomics, Inc.

Molecular Karyotyping Technology Expected to Drive Advances in Prenatal and Neonatal Research and Disease Detection


PerkinElmer, Inc. announced the acquisition of the assets of Spectral Genomics, Inc., a company focussing on molecular karyotyping technology used to evaluate chromosomal abnormalities. Terms of the deal were not disclosed.

Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders. The company's proprietary Array CGH (Comparative Genome Hybridization) technology provides a high-resolution global view of the human genome, enabling researchers to identify the exact location of any chromosomal deletions and amplifications that can cause an increased risk of genetic disease.

According to PerkinElmer, array-based karyotyping is widely expected to replace Florescent In-Situ Hybridization (FISH), G-banding microscopic analysis and other conventional forms of karyotyping in the cytogenetic market.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy